Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma

NCT03260504 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03260504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03260504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Terminated
Start date
August 28, 2018
Completion date
July 26, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, metastatic clear cell renal cell carcinoma, stage iii renal cell cancer, stage iv renal cell cancer